Smithwise and Catapult have joined teams to become Archimedic! Read More.

Epinephrine Delivery System

A 2018 study by the Univ. of Southern California showed that half of adults with severe food allergies haven't had their EpiPen® or other auto-injector with them during their most severe attack. 

Dr. Edmund Pribitkin, CMO of Thomas Jefferson University Hospitals, approached Archimedic (then Smithwise) with a proposed solution--embedding an auto-injector for epinephrine into the case of a smartphone. 

This project is based on an issued US patent held by Thomas Jefferson University, US 10,022,506.

Jefferson is currently pursuing partnership opportunities for this device. For further information, please click here.





Medtech Leaders Trust Archimedic